ALK and anaplastic large cell lymphoma: Crizotinib has been explored in the treatment of pediatric ALK+ ALCL patients with positive efficacy and safety profiles (170), with results demonstrating its utility in inducing complete remissions in the setting of advanced, relapsed ALK-positive ALCL cases (171, 172).